12/31/2008 | SS | SAC Capital reports 7.1% stake in Pharmion
|
3/7/2008 | SS | Celgene, Pharmion combine
|
3/7/2008 | SS | Market Commentary: Vultures circle WaMu; Deutsche Telekom may call on Sprint; pilots renew seniority talks; Pharmion closes
|
3/6/2008 | SS | Pharmion, Celgene merger set to close Friday
|
3/5/2008 | SS | SAC sells more shares of Pharmion
|
2/29/2008 | SS | SAC Capital sells more than 83,000 shares of Pharmion
|
2/19/2008 | SS | Pharmion shareholders to decide Celgene merger on March 6
|
2/15/2008 | SS | Farallon buys shares of Pharmion
|
2/8/2008 | SS | Baker brothers report sale of Pharmion stock
|
2/6/2008 | SS | Pharmion shareholder seeks to delay Celgene merger vote
|
2/1/2008 | SS | Farallon owns more than 2.3 million shares of Pharmion
|
1/28/2008 | SS | Celgene, Pharmion merger closer to completion
|
1/15/2008 | SS | SAC Capital boosts stake in Pharmion
|
1/3/2008 | SS | Celgene, Pharmion merger clears waiting period hurdle
|
11/19/2007 | SS | Market Commentary: Celgene, Pharmion to merge, sending shares of Pharmion up; Quanex stock spikes on merger, spinoff
|
11/19/2007 | SS | Celgene to expand in hematology, oncology markets with $2.9 billion acquisition of Pharmion
|
5/2/2007 | CV | Pharmion files automatic shelf registration
|
10/25/2006 | BT | Pharmion says cash adequate to continue in-licensing, develop current pipeline
|
9/25/2006 | BT | Market Commentary: Acorda skyrockets on trial data; GPC, Pharmion, Spectrum rise; Dendreon steady on rivals' news
|
9/25/2006 | BT | Spectrum, GPC Biotech, Pharmion say satraplatin trial in prostate cancer yields positive results
|
9/15/2006 | BT | Pharmion, MethylGene begin phase 2 trial of MGCD0103 in lymphoma
|
7/25/2006 | BT | Pharmion second-quarter net sales up at $60.4 million
|
6/13/2006 | BT | FDA accepts Pharmion's NDA supplement for IV administration of Vidaza
|
6/8/2006 | BT | Pharmion, GPC Biotech, Spectrum: Monitoring board recommends satraplatin phase 3 trial continue
|
6/7/2006 | BT | Pharmion presents results from several studies of Vidaza in cancer
|
6/6/2006 | BT | GPC Biotech, Pharmion, Spectrum say new satraplatin clinical data shows cancer drug well-tolerated
|
6/5/2006 | BT | Pharmion reports some patients see bone marrow benefits with MGCD0103
|
5/17/2006 | BT | GPC Biotech, Pharmion recommended for analysis of satraplatin phase 3 trial
|
5/16/2006 | BT | Pharmion, GPC begin phase 1 trial of satraplatin with Xeloda in patients with advanced solid tumors
|
3/30/2006 | BT | Pharmion seeks FDA OK to administer Vidaza intravenously
|
2/28/2006 | BT | Pharmion to file marketing application for satraplatin for prostate cancer
|
2/27/2006 | BT | GPC, Pharmion announce new data that shows satraplatin effective in prostate cancer patients
|
1/30/2006 | BT | MethylGene, Pharmion announce licensing agreement for oncology HDAC inhibitors
|
1/23/2006 | BT | Spectrum, GPC Biotech license cancer drug satraplatin to Pharmion
|
1/10/2006 | BT | Pharmion will use phase 3 results to file MAA for thalidomide
|
12/22/2005 | BT | Pharmion signs Vidaza manufacturing pact with Ben Venue Laboratories
|
12/20/2005 | BT | GPC Biotech signs pact for cancer drug with Pharmion
|
12/13/2005 | BT | Pharmion's thalidomide combo shows 76% response rate in myeloma study
|
12/12/2005 | BT | Pharmion says analyses demonstrate safety, effectiveness of Vidaza in treating blood cancers
|